REFERENCE FILE
Retatrutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Investigational
- Evidence category
- Randomized evidence
- Mechanism
- Activates GIP, GLP-1 and glucagon receptors.
- Evidence
- A randomized obesity trial was funded by Lilly.
- Limitations
- Trial averages do not predict an individual outcome.
- Safety
- The trial reported gastrointestinal adverse events.
- Formulation and route
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
A SECOND LOOK
A question to carry into the reading
When reading the retatrutide profile, turn uncertainty into a specific question rather than a single label. If a passage seems tentative, ask whether the uncertainty concerns the size of a result, its explanation, its consistency, or its relevance to the question you brought. Different gaps call for different evidence. State what additional observation would help resolve the particular gap, without assuming that evidence exists. You can then separate what the citation supports from what you would still like to know. This makes uncertainty useful: it identifies the next question instead of becoming either reassurance or a reason to dismiss everything.
Questions to keep beside the page
- Which part of the statement is uncertain: its size, explanation, consistency, or relevance?
- What additional observation would help answer that specific unresolved question?
- Am I treating an unanswered question as though it already has an answer?
Sources for this file
- FDA GLP-1FDA · Checked
- JastreboffPubMed · Checked
FROM THE REFERENCE DESK